Focus area
Breast cancer is the most-diagnosed cancer in women worldwide. Dr. Memari's practice combines oncologic resection with oncoplastic and reconstructive technique — so that complete cancer treatment and a good long-term breast appearance are planned together.
2.3M
new cases worldwide each year
WHO / GLOBOCAN
~1 in 20
women diagnosed in their lifetime
WHO
670,000
deaths worldwide in 2022
WHO
> 90%
5-year survival for localized disease in high-HDI regions
GLOBOCAN
Breast cancer is also one of the most curable cancers when detected early. The gap between outcomes in high- and low-income regions is driven mostly by access to screening, timely diagnosis, and multidisciplinary treatment — not by biology. A well-coordinated team and surgical plan matter as much as the drugs used afterward.
Removes the tumor with a margin of healthy tissue while preserving the rest of the breast. Usually combined with radiotherapy and, when oncologically appropriate, with oncoplastic reshaping of the remaining tissue.
Typical indication: Early-stage invasive cancer and DCIS where tumor size and location allow clear margins with good cosmetic outcome.
Removes the entire breast when breast-conserving surgery is not appropriate. Skin- and nipple-sparing variants preserve the breast envelope for immediate reconstruction and better aesthetic outcome.
Typical indication: Larger or multifocal tumors, extensive DCIS, inflammatory disease, high-risk genetic mutations (e.g. BRCA1 / BRCA2), or patient preference.
Combines cancer resection with plastic-surgery technique — tissue rearrangement, volume replacement, symmetrization — in the same operation, so the treated breast keeps a natural shape. Immediate or delayed autologous / implant-based reconstruction is planned with the patient.
Typical indication: Larger lumpectomy defects, unfavorable tumor-to-breast volume ratio, or patients prioritizing aesthetic outcome alongside oncologic clearance.
Identifies and removes only the first (sentinel) lymph node(s) draining the tumor to check for spread, avoiding the complications of a full axillary dissection when the sentinel nodes are clear.
Typical indication: Clinically node-negative breast cancer; modern fluorescent / radioisotope mapping improves accuracy and lowers lymphedema risk.
Most of these findings are not cancer, but they should always be evaluated. Early assessment widens the available treatment options and usually improves the long-term outcome.
Each patient is discussed in a multidisciplinary context (surgery, oncology, radiology, pathology) before the operative plan is set. Whenever it is oncologically safe, breast-conserving and oncoplastic techniques are preferred over mastectomy. When mastectomy is the right choice, skin- and nipple-sparing approaches with immediate reconstruction are considered to preserve quality of life. Follow-up combines standard surveillance with the patient-reported-outcome monitoring tools that feature in Dr. Memari's digital-health research.
Discuss a caseFigures: WHO breast-cancer fact sheet, GLOBOCAN 2022, and peer-reviewed reviews.